Malaria,FalciparumPhase 1/2NCT03896724
Safety, Immunogenicity and Efficacy of R21 Matrix-M in 5-17 Month Old Children in Nanoro, Burkina Faso
A Phase 1/2 study testing R21 adjuvanted with 25mcg Matrix-M, Rabies Vaccine and R21 adjuvanted with 50mcg Matrix-M in people with Malaria,Falciparum, run by University of Oxford at 1 site in Burkina Faso.
Trial summary
This is a double blind randomised controlled clinical trial to evaluate the efficacy of R21 adjuvanted with Matrix-M in healthy 5-17 month old children in a malaria endemic area. Read more about this study
- Who is it for?
- Ages 5 to 17 monthsHealthy volunteers can take part
- Conditions the study is for
- Malaria,Falciparum
- What is being tested?
- R21 adjuvanted with 25mcg Matrix-M, Rabies Vaccine and R21 adjuvanted with 50mcg Matrix-M
- Type of treatment
- Vaccines
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 450 participants
- Where
- 1 siteBurkina Faso
- Study dates
- 7 May 2019to 7 Jul 2023
- Phase
- Phase 1/2
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 5 to 17 months
- All sexes
- Healthy volunteers accepted
- Child
Who may be able to join
- Healthy child aged 5-17 months at the time of first study vaccination
- Provide written Informed consent of parent/guardian
- Child and parent/guardian resident in the study area villages and anticipated to be available for vaccination and follow-up for 2 years following last dose of vaccination
Who cannot join
- Clinically significant skin disorder (psoriasis, contact dermatitis etc.), immunodeficiency, cardiovascular disease, respiratory disease, endocrine disorder, liver disease, renal disease, gastrointestinal disease, neurological illness.
- Weight-for-age Z score of less than -3 or other clinical signs of malnutrition.
- History of allergic reaction, significant IgE-mediated event, or anaphylaxis to immunisation.
- History of allergic disease or reactions likely to be exacerbated by any component of the vaccines, e.g. neomycin.
- Sickle cell disease.
- Clinically significant laboratory abnormality as judged by the study clinician.
Show all 14Show fewer
- Blood transfusion within one month of enrolment.
- Administration of immunoglobulins and/or any blood products within the three months preceding the planned administration of the vaccine candidate.
- Previous vaccination with experimental malaria vaccines.
- Participation in another research study involving receipt of an investigational product in the 30 days preceding enrolment, or planned use during the study period.
- Current participation in another clinical trial, or within 12 weeks of this study.
- Known maternal HIV infection (No testing will be done by the study team).
- Any confirmed or suspected immunosuppressive or immunodeficient state, including HIV infection; asplenia; recurrent, severe infections and chronic (more than 14 days) immunosuppressant medication within the past 6 months (For corticosteroids, this will mean prednisone, or equivalent, >= 0.5 mg/kg/day. Inhaled and topical steroids are allowed).
- Any significant disease, disorder or situation which, in the opinion of the Investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant's ability to participate in the trial.
Trial locations and contacts
1 site in 1 country.
Burkina Faso1 site
Institut de Recherche en Sciences de la Sante - Clinical Research Unit of Nanoro (IRSS-URCN)
Nanoro
About this study
Official title: A Phase Ib/IIb Randomised Controlled Trial of the Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine, R21 Adjuvanted With Matrix-M (R21/MM), in 5-17 Month Old Children in Nanoro, Burkina Faso
This is a double blind randomised controlled clinical trial to evaluate the efficacy of R21 adjuvanted with Matrix-M in healthy 5-17 month old children in a malaria endemic area.
Read the detailed description
In this double-blind, randomised, controlled, phase 2b trial, the low-dose circumsporozoite protein-based vaccine R21, with two different doses of adjuvant Matrix-M (MM), was given to children aged 5-17 months in Nanoro, Burkina Faso-a highly seasonal malaria transmission setting. Three vaccinations were administered at 4-week intervals before the malaria season, with a fourth dose 1 year later. All vaccines were administered intramuscularly into the thigh. Group 1 received 5 μg R21 plus 25 μg MM, group 2 received 5 μg R21 plus 50 μg MM, and group 3, the control group, received rabies vaccinations. Children were randomly assigned (1:1:1) to groups 1-3. An independent statistician generated a random allocation list, using block randomisation with variable block sizes, which was used to assign participants. Participants, their families, and the local study team were all masked to group allocation. Only the pharmacists preparing the vaccine were unmasked to group allocation. Vaccine safety, immunogenicity, and efficacy were evaluated over 1 year. The primary objective assessed protective efficacy of R21 plus MM (R21/MM) from 14 days after the third vaccination to 6 months.
From May 7 to June 13, 2019, 498 children aged 5-17 months were screened, and 48 were excluded. 450 children were enrolled and received at least one vaccination. 150 children were allocated to group 1, 150 children were allocated to group 2, and 150 children were allocated to group 3. The final vaccination of the primary series was administered on Aug 7, 2019. R21/MM had a favourable safety profile and was well tolerated.
Please see publication for more details: Lancet. 2021 May 15;397(10287):1809-1818. doi: 10.1016/S0140-6736(21)00943-0
After the first booster vaccination, participants in Groups 1 and 2 were further randomised 2:1 to receive R21 with Matrix-M: control. The trial was extended by a further two years with yearly boosters of R21/MM or rabies vaccine. Groups 1 and 2 were subdivided and randomized 2:1 to receive R21/MM or rabies vaccine as the second booster. Group 3 received control rabies vaccine as they had done previously. The second boosting occurred between June and July 2021 where 368 participants were boosted. In May 2022 it was decided to amend the protocol to allow for groups 1a and 2a (malaria vaccine groups) to be randomised 1:1 to receive either the R21/Matrix-M vaccine or a control rabies vaccine a year after the previous booster vaccine. The third boosting occurred between June and July 2022 where 357 participants were boosted.
Between June 2, and July 2, 2020, 409 children returned to receive a booster vaccine. Each child received the same vaccination for the booster as they received in the primary series of vaccinations; 132 participants received 5 μg R21 adjuvanted with 25 μg Matrix-M, 137 received 5 μg R21 adjuvanted with 50 μg Matrix-M, and 140 received the control vaccine.
A booster dose of R21/Matrix-M at 1 year following the primary three-dose regimen was administered. The trial is ongoing to assess long-term follow-up of these participants and the value of further booster
Please see publication for more details of results of two year follow up: Lancet Infect Dis. 2022 Dec;22(12):1728-1736. doi: 10.1016/S1473-3099(22)00442-X.
VAC076 is complete, with the last volunteer last visit occurring in July 2023. This trial was funded by the European and Developing Countries Clinical Trials Partnership (reference: RIA2016V-1649 MMVC).
- Conditions
- Malaria,Falciparum
- Being tested
- R21 adjuvanted with 25mcg Matrix-M, Rabies Vaccine, R21 adjuvanted with 50mcg Matrix-M
- Medical subject headings
- Malaria, Falciparum
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
R21 adjuvanted with 25mcg Matrix-MBiological
Vaccine
Rabies VaccineBiological
Vaccine
R21 adjuvanted with 50mcg Matrix-MBiological
vaccine
| Study group | Role | What they receive |
|---|---|---|
| Group 1 | Experimental | n=150. Age 5-17 month-old. 5mcg R21/25mcg Matrix-M at Day 0, 28 and 56 and 1 year.
Following the initial booster, Group 1 will be randomised 2:1 into Groups1a and 1b for 5ug R21/50ug Matrix-M: control. Groups 1a and 1b will receive these second and third booster vaccinations each year prior to the malaria season Receives: Biological: R21 adjuvanted with 25mcg Matrix-M; Biological: Rabies Vaccine; Biological: R21 adjuvanted with 50mcg Matrix-M |
| Group 2 | Experimental | n=150. Age 5-17 month-old. 5mcg R21/50mcg Matrix-M at Day 0, 28 and 56 and 1 year.
Following the initial booster, Group 2 will be randomised 2:1 into Groups 2a and 2b or 5ug R21/50ug Matrix-M:ccontrol. Groups 2a and 2b will receive these second and third booster vaccinations each year prior to the malaria season Receives: Biological: Rabies Vaccine; Biological: R21 adjuvanted with 50mcg Matrix-M |
| Group 3 (control group) | Placebo comparator | n=150. Age 5-17 month-old. Rabies Vaccine by the end of the trial. Receives: Biological: Rabies Vaccine |
What is being measured
The primary outcome is the main question the study is designed to answer.
The protective efficacy (number of cases) against clinical malaria of R21 adjuvanted with Matrix-M in 5-17 month old children living in a malaria-endemic area
We will look for the presence of axillary temperature ≥37.5°C AND P. falciparum parasites density > 5000 asexual forms/µL as a primary case definition of clinical malaria.
- We will look for the presence of axillary temperature ≥37.5°C and/ or history of fever within the last 24 hours AND P. falciparum parasites density > 0 for a secondary case definition of clinical malaria.
Measured: for 6 months after the last vaccination
Secondary outcomes (4)
Duration of Protective efficacy (number of cases) against clinical malaria
To assess the protective efficacy (number of cases) against clinical malaria of R21 adjuvanted with Matrix-M in 5-17 months old children living in a malaria-endemic area
Measured: for 12 months after administration of the third dose of vaccine, and for 6 and 12 months after each booster vaccination
Efficacy (number of cases) against asymptomatic P. falciparum infection
Primary case definition of asymptomatic P. falciparum infection: Presence of axillary temperature < 37.5°C and absence of history of fever within the last 24 hours; AND P. falciparum parasites density > 0 asexual forms/µL
Measured: at 6 and 12 months after administration of the third dose of vaccine, and for 12 months after each booster vaccination
The safety and reactogenicity (number of adverse events) of R21 adjuvanted with Matrix-M in 5-17 month olds living in a malaria-endemic area in the month following each vaccination and at 12 months after administration of the final dose of vaccine
- Occurrence of solicited local and/or systemic reactogenicity signs and symptoms for 7 days following the vaccination
- Occurrence of unsolicited adverse events for 28 days following the vaccination
- Occurrence of serious adverse events for the duration of the trial
Measured: for 6 and 12 months after administration of the third dose of vaccine, and for 12 months after each booster vaccination
The humoral immunogenicity (antibody response) of R21 adjuvanted with Matrix-M in 5-17 months old children living in a malaria-endemic area
- Comparison of immunogenicity (antibody responses to CSP) in the R21/MM vaccination group with those in the rabies vaccine group and the durability of responses
- ELISA to quantify antibodies to the vaccine components (regions of the CS antigen including the NANP repeat region and other elements of the protein as well as anti HBs).
Measured: for 6 and 12 months after administration of the third dose of vaccine, and for 6 months after each booster vaccination
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Apr 2019
- Study start7 May 2019
- Primary completion7 Jul 2023
- Study completion7 Jul 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for Malaria,FalciparumStudies of the same condition, open and under way.
- More trials run by University of OxfordThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1/2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 450 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Oxford
- Sponsor type
- University, hospital or other
- Collaborators
- Institut de Recherche en Sciences de la Sante, Burkina Faso, European and Developing Countries Clinical Trials Partnership (EDCTP)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03896724
- Sponsor's protocol ID
- VAC076
- Status last verified
- Jul 2025
- First submitted
- 18 Jan 2019
- Last updated
- 11 Jul 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Study information will be made available through an open repository. The information to be made available will be anonymized so that there is no link to participants and will include data on safety, immune responses and any other data generated from samples obtained in this study.
Publications
Mukhopadhyay ES, Bellamy DG, Tinto H, Hamaluba M, Truby A, Salman AM, Hill AVS. Naturally acquired immune responses to alpha-gal in malaria endemic settings and pre-clinical efficacy testing with R21/MM. Vaccine. 2025 Dec 5;68:127897. doi: 10.1016/j.vaccine.2025.127897. Epub 2025 Nov 1.
PubMed 41176969Datoo MS, Natama HM, Some A, Bellamy D, Traore O, Rouamba T, Tahita MC, Ido NFA, Yameogo P, Valia D, Millogo A, Ouedraogo F, Soma R, Sawadogo S, Sorgho F, Derra K, Rouamba E, Ramos-Lopez F, Cairns M, Provstgaard-Morys S, Aboagye J, Lawrie A, Roberts R, Valea I, Sorgho H, Williams N, Glenn G, Fries L, Reimer J, Ewer KJ, Shaligram U, Hill AVS, Tinto H. Efficacy and immunogenicity of R21/Matrix-M vaccine against clinical malaria after 2 years' follow-up in children in Burkina Faso: a phase 1/2b randomised controlled trial. Lancet Infect Dis. 2022 Dec;22(12):1728-1736. doi: 10.1016/S1473-3099(22)00442-X. Epub 2022 Sep 7.
PubMed 36087586Datoo MS, Natama MH, Some A, Traore O, Rouamba T, Bellamy D, Yameogo P, Valia D, Tegneri M, Ouedraogo F, Soma R, Sawadogo S, Sorgho F, Derra K, Rouamba E, Orindi B, Ramos Lopez F, Flaxman A, Cappuccini F, Kailath R, Elias S, Mukhopadhyay E, Noe A, Cairns M, Lawrie A, Roberts R, Valea I, Sorgho H, Williams N, Glenn G, Fries L, Reimer J, Ewer KJ, Shaligram U, Hill AVS, Tinto H. Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial. Lancet. 2021 May 15;397(10287):1809-1818. doi: 10.1016/S0140-6736(21)00943-0. Epub 2021 May 5.
PubMed 33964223